Navigation Links
High-Throughput System Generates Ultra-Pure PCR Products Suitable for All,,,Applications

l. As seen in Figure 2, the wells that were processed without samples show no contamination products from adjacent wells. Furthermore, the ethidium bromide staining contaminant present in the unpurified sample, migrating in advance of the 250-bp marker (Lane 2), is eliminated from wells of the StrataPrep 96 plate (Lanes 3, 5, 7, 9, 11, and 13).

Fig.2

Consistent Results in Variable Conditions

The performance of the StrataPrep 96 PCR kit was evaluated by first determining the DNA binding capacity of the kits binding plate. Increasing quantities of linear double-stranded plasmid DNA were loaded into plate wells. The wells were washed, DNA was eluted, and the recovered DNA was quantitated by UV spectrophotometry (data not shown). The maximum amount of DNA recovered was 5 g per well. The size range of DNA recovered was also determined by loading a mixture of linear double-stranded DNA ranging in size from 115 bp to 23,000 bp into each well of the binding plate. The plate was washed, DNA was eluted, and DNA recovery from 15 randomly chosen wells was assessed by gel electrophoresis. Figure 3 shows uniform recovery of all DNA sizes from the wells of the plate.

Fig.3

One time-consuming step in most purification schemes is removing the oil overlay from amplification reactions. Although this step is a nuisance, it is often essential for recovering PCR products of sufficient purity for subsequent applications. Without modifying the standard purification procedure, this variable was examined by purifying two 50-l amplification reactions, one with and one without the oil overlay. An equal volume of DNA binding solutio
'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
2. Highest Possible Transformation Efficiencies for High-Throughput Applications
3. High-Throughput Cultivation of Bacterial Clones
4. High-Throughput Isolation of Total RNA
5. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
6. Advantages of ReadyAgarose Precast Gels Over 96-Well Handcast Gels for High-Throughput Analysis, Rev A
7. New Mammalian Two-Hybrid System Detects Protein-Protein Interactions
8. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
9. Generate Adenovirus Vectors in E. coli by Homologous Recombination with the AdEasy Adenoviral Vector System
10. New Yeast Cloning System for Producing Proteins with Native Amino Acid Sequences
11. Enhanced PCR Cloning System

Post Your Comments:
(Date:11/5/2009)... GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ ...ts financial results for the third quarter ended S...3.6 million ($0.04 per share) for the three months...f $6.8 million ($0.08 per share) in the comparable...ber 30, 2009, GenVec,s net loss was $14.1 million ...
(Date:11/5/2009)... PARSIPPANY, N.J., Nov. 5 DSM Phar...de a manufacturing alliance with Galenix, Saint Je...d commercial scale manufacturing partner for Galen...M and Galenix will collaborate on business develop...ery technologies, based on the strength of Galenix...
(Date:11/5/2009)... RANCHO CORDOVA, Calif., Nov. 5 /PRNewswire-FirstC...ading supplier of innovative products for processi...sults for the first quarter of fiscal 2010. ,, ...any reported revenues of $5.2 million, a 15 percen...rst quarter a year ago. The Company said the key c...
(Date:11/5/2009)... OMAHA, Neb., Nov. 5 Tra...nnounced financial results for the quarter ended S... are presented in the tables that follow. ,, T...t loss of $366,000 or $0.01 per share for the thir...9,000 or $0.01 per share for the third quarter of ...
Breaking Biology Technology:GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...2 Nektar,Therapeutics (Nasdaq: NKTR ) announced ...nsition from a drug delivery service provider to a...estructuring will,streamline the company, consolid...aking and execution within the business units., "... development company,and these changes are a natur...
...formance in 2007 and Notes Achievements over 4-ye... BioSciences, Preparing for Cha...ing-Plough,Corporation (NYSE: SGP ) today reporte...d full year, and commented on its ongoing integrat...cquired in November 2007 and,includes the Organon ...
...nternational,Corporation (Nasdaq: PRXL ) announce... 2-for-1 split of its Common Stock, which will be ...ers of PAREXEL,s Common Stock will receive one add...mmon Stock held on the record date of,February 22,...n or about,March 3, 2008 by PAREXEL,s transfer age...
Other Biology Technology:Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 2Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 3Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 2Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 3Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 4Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 5Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 6Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 7Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 8Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 9Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 10Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 11Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 12Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 13Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 14Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 15Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 16Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 17Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 18Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 19Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 20Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 21Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 22Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 23Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 24Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 25Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 26Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 27Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 28PAREXEL International Announces 2-For-1 Stock Split 2PAREXEL International Announces 2-For-1 Stock Split 3
(Date:11/4/2009)... 2009 Childhood obesity in the United States is r...ourth of advertising on daytime and prime time tel...ing questions about the role television plays in o...the Journal of Nutrition Education and Behavior ...ght be a large contributor to the problem. , Res...
(Date:11/4/2009)...hat deciphered the DNA codes, or genomes, of the f...joined The Genome 10K Project, an international ef...ences on 10,000 species of animals for conducting ...not be achieved. , Participating in The Genome 1...Nov. 5, 2009 issue of the Journal of Heredity , a...
(Date:11/4/2009)..., Oct. 19 Spectros, developer and ...ging devices which shed light on life-threatening ...sive distribution deals for both its T-Stat® ...red include Australia, New Zealand, The Netherlan..., France, Spain, Portugal, Poland, Greece, Turkey,...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Singapore scientists join international study of 10,000 vertebrates' genomes 2Spectros Signs New International Distribution Deals 2Donor Sperm Providers Form New Non Profit 59569 1Oaks Development Group Launches Physician Incubator Space in Palm Coast Medical Office Building 59566 1Oaks Development Group Launches Physician Incubator Space in Palm Coast Medical Office Building 59566 2MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 14494 1MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 14494 2MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 14494 3
...reasing amounts of ice mass have been lost from We... past ten years, according to research from the Un... in Nature Geoscience. , Meanwhile the ice mass ...either loss nor accumulation over the past decade.... Bristol and colleagues estimated the flux of ice ...
...N ARBOR, Mich.---Common genetic variants linked to... new study shows. , The international study was c...ic Health. The journal Nature Genetics will publis...onfirms observations by health professionals of a ...risk of osteoarthritis, the most common form of ar...
...tudies involving more than 35,000 people and a sur...al team supported in part by the National Institut...genetic variants recently linked to osteoarthritis...indings were released today in the advance online ...e variants most strongly associated with height in...
Other Biology News:Antarctic ice loss 2Study suggests genetic connection between short stature and arthritis 2Researchers uncover new piece to the puzzle of human height 2Researchers uncover new piece to the puzzle of human height 3Researchers uncover new piece to the puzzle of human height 4
...tion. Cleaves a-(1-3)- and a(1-6)-linked, non-r...tes and glycoproteins. It is particularly efficien... where the pH must be neutral or above, for exampl...will hydrolyze 1 mole of p-nitrophenyl a-D-galacto...
ABI3100 Adapter for ABgene from ABgene
...2-Naphthoyl-VF-CHO White lyophilized solid. PROT...ermeable, reversible inhibitor of γ-secretas...40 (ED 50 = 2.6 μM) and Aβ x-42 (ED 50 ...ith the Amyloid Precursor Protein Swedish mutants....
Acl I (Psp1406 I) from New England Biolabs
Biology Products: